Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806286 · ClinicalTrials.gov registry record · Phase 2
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00806286 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 111 participants.
The verdict
NCT00806286, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. The study will find out if adding CS-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in subjects with metastatic non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Placebo Tablets
- DRUG CS7017 tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806286
The ClinicalTrials.gov registry entry for NCT00806286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00806286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806286 about?
NCT00806286 is a clinical study titled "Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer". The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receiv...
What is the current status of trial NCT00806286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2008-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00806286?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Placebo Tablets (DRUG), CS7017 tablets (DRUG).
Who is sponsoring clinical trial NCT00806286?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.